Information Provided By:
Fly News Breaks for February 17, 2017
CELG
Feb 17, 2017 | 08:02 EDT
Credit Suisse analyst Alethia Young believes Celgene has a broad pipeline that will yield some real winners and ultimately the pipeline can address Revlimid's patent loss. The analyst remains confident that the company has a coherent strategy to replace hematology revenues as well, and says Celgene remains a top franchise pick and on her firm's focus list. Out of her entire coverage, Young thinks Celgene has the "strongest potential" to have a transformational business in 5 years or less. She reiterates an Outperform rating and $148 price target on the shares.
News For CELG From the Last 2 Days
There are no results for your query CELG